Results 141 to 150 of about 832,259 (254)

Genetic Engineering of Tumor‐Infiltrating Lymphocytes (TIL) via a T‐Editor Platform to Enhance Anti‐Tumor Activity

Cancer Science, EarlyView.
A rapid and efficient CRISPR‐mediated gene editing platform for TIL engineering identified FAM84B as a novel potential target to enhance antitumor activity and pioneered the use of CBE to generate FAM84B loss‐of‐function TIL with enhanced antitumor activity.
Fenge Li, Xuejiao Ma, Yongming Xue, Jilong Yang, Ruijing Wang, Xiang Li, Chao Zhang, Wenhan Lu, Mei Liu, Yue Xu, Xinyi Wang, Shengnan Wu, Ning Kang, Chunhua Ma   +13 more
wiley   +1 more source

Cord Blood‐Derived Fibroblast Activation Protein‐Targeted Chimeric Antigen Receptor Natural Killer Cells Persist in Vivo

Cancer Science, EarlyView.
We generated cord blood‐derived FAP‐targeted CAR NK cells and evaluated their activity against cancer‐associated fibroblasts. These cells showed antigen‐specific cytotoxicity in vitro and robust persistence in a pleural dissemination model, although in vivo anti‐CAF efficacy was limited, supporting further development of stromal‐targeted cellular ...
Takashi Hiroshima, Toru Kimura, Mariko Maekawa, Mayuko Noguchi, Takahiro Matsui, Shunya Ikeda, Makiko Suga, Hideki Nagata, Kenji Kimura, Eriko Fukui, Takashi Kanou, Naoko Ose, Eiichi Morii, Yasushi Shintani, Naoki Hosen   +14 more
wiley   +1 more source

Advances in the Role of Chemokines in Microwave Ablation‐Based Combinatorial Immunotherapy

Cancer Science, EarlyView.
MWA can initiate antitumor immunity through tumor antigen release and innate immune activation, but iMWA may instead promote an immunosuppressive microenvironment. Combining MWA with immunotherapeutic strategies offers a promising approach to enhance systemic immunity and suppress residual and distant tumors.
Ruijie An, Ningning He, Wendong Gu
wiley   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells

Chimeric antigen receptor-expressing NK (CAR-NK) cells represent an advancing frontier in cancer immunotherapy, building upon decades of natural killer cell research and recent breakthroughs in CAR technology.
Supreet Khanal, Nirjal Bhattarai
core   +1 more source

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy

Cancer Science, EarlyView.
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao, Dingyao Hu, Jie Lv, Jin Chai, Yue Wang, Jie Chen, Xiaoqiang Yan, Jun Zhu, Hui Yu   +8 more
wiley   +1 more source

CAR-NK cell therapy for hematological malignancies. [PDF]

Blood Adv
Manzar GS, Hasan MF, Moore M, Tiberti S, Basar R, Daher M.   +5 more
europepmc   +1 more source

iPSC‐Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice

Cell Proliferation, EarlyView.
Infusion of CXCR4‐expressing iNK progenitor (iNKP) cells derived from iPSCs can continuously generate iNK cells in an unconditioned and autologous PBMC humanised hIL15 mouse model. iNKP cell therapy has the potential to treat patients without the requirement for prior lymphodepletion. ABSTRACT NK cells exhibit inherently short persistence in vivo. Allo‐
Min Zhang, Zhiqian Wang, Yanhong Liu, Leqiang Zhang, Fangxiao Hu, Chengxiang Xia, Mengyun Zhang, Tongjie Wang, Qitong Weng, Hanmeng Qi, Yanping Zhu, Lijuan Liu, Dehao Huang, Hong‐Hu Zhu, Jinyong Wang   +14 more
wiley   +1 more source

From dual targeting to dynamic targeting: Rethinking CAR-NK cell therapy for pancreatic cancer. [PDF]

Mol Ther Oncol
Rallis KS, Dionisio LM, Tarannum M, Romee R, Cancelas JA.   +4 more
europepmc   +1 more source

Lactate and Lactylation: What We Know and What We Expect in Tumour Progression

Cell Proliferation, EarlyView.
Lactate and lactylation in cancer cells have been shown to accelerate tumour development in various ways, including stemness generation, metabolic dysregulation, cell death, chemotherapy resistance, and cell cycle disorder. In addition, lactate and lactylation promote angiogenesis and create an immunosuppressive microenvironment, which promotes tumour ...
Qi Zhang, Zhenzhen Han, Youjia Duan
wiley   +1 more source